Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Dropbox Announces Fiscal 2019 First Quarter Results – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Dropbox Announces Fiscal 2019 First Quarter Results

Published

on

Reading Time: 13 minutes

Revenue of $385.6 Million, Up 22% Year-over-year

Net Cash Provided by Operating Activities of $63.2 Million and Free Cash
Flow of $33.5 Million

SAN FRANCISCO–(BUSINESS WIRE)–Dropbox, Inc. (NASDAQ: DBX), a leading global collaboration platform,
today announced financial results for its first fiscal quarter ended
March 31, 2019.

We kicked off 2019 with a strong Q1, driven by continued paying user
growth and ARPU expansion,” said Dropbox Co-founder and Chief Executive
Officer Drew Houston. “Our 22% top line growth and robust operating
margins reflect our efficient go-to-market strategy and operational
discipline. We’ve reached a scale few SaaS companies have achieved and
continue to ship product experiences that put Dropbox at the center of
our users’ workflows. We also closed our first acquisition as a public
company with HelloSign, and I’m excited about our future together.”

Advertisement
Stake.com

First Quarter Fiscal 2019 Results

  • Total revenue was $385.6 million, an increase of 22% from the same
    period last year.
  • Paying users totaled 13.2 million, inclusive of 0.1 million
    incremental paying users from our acquisition of HelloSign, as
    compared to 11.5 million for the same period last year. Average
    revenue per paying user was $121.04, as compared to $114.30 for the
    same period last year.
  • GAAP gross margin was 74.5%, as compared to 61.9% in the same period
    last year. Non-GAAP gross margin was 75.4%, as compared to 74.2% in
    the same period last year. (1)
  • GAAP operating margin was (5.5%), as compared to (147.3%) in the same
    period last year. Non-GAAP operating margin was 10.1%, as compared to
    10.9% in the same period last year. (1)
  • GAAP net loss was ($7.7) million, as compared to ($465.5) million in
    the same period last year. Non-GAAP net income was $41.7 million, as
    compared to $30.9 million in the same period last year. (1)
  • Net cash provided by operating activities was $63.2 million, as
    compared to $61.8 million in the same period last year. Free cash flow
    was $33.5 million, as compared to $51.9 million in the same period
    last year.
  • GAAP basic and diluted net loss per share was ($0.02), as compared to
    ($2.13) in the same period last year. Non-GAAP diluted net income per
    share was $0.10, as compared to $0.08 in the same period last year. (1)(2)
  • Cash, cash equivalents and short-term investments were $915.2 million
    at the end of the first quarter of 2019.

(1) Our first quarter of 2018 results include the impact of
stock-based compensation related to two-tier restricted stock units
(“RSUs”). These awards had both a service-based vesting condition and a
liquidity event-related performance condition. The liquidity
event-related performance condition was satisfied upon our IPO. As a
result, we recognized $418.7 million in stock-based compensation expense
related to two-tier RSUs for which the service-based vesting condition
had been met as of the end of the first quarter of 2018. During the
first quarter of 2018, we also released 26.8 million shares of common
stock underlying the vested two-tier RSUs, and as a result recorded
$13.9 million in employer related payroll tax expenses associated with
these same awards.

(2) Non-GAAP diluted net income per share is calculated based
upon 417.7 million and 373.1 million diluted weighted-average shares of
common stock for the three months ended March 31, 2019 and 2018,
respectively.

HelloSign Acquisition

Dropbox completed the acquisition of JN Projects, Inc. (d/b/a HelloSign)
(“HelloSign”), which provides an e-signature and document workflow
platform, on February 8, 2019 for $230 million, consisting primarily of
cash payments, subject to customary purchase price adjustments. Of
the $230 million of consideration, $48.5 million is subject to on-going
employee service. The acquisition of HelloSign expands our content
collaboration capabilities to include additional business-critical
workflows.

Adoption of ASC 842

Advertisement
Stake.com

We adopted the new leasing standard, ASC 842, on January 1, 2019, which
resulted in the recognition of operating right-of-use assets of $431.7
million and operating lease liabilities of $502.4 million on the
condensed consolidated balance sheet. We elected to use the optional
transition method relating to comparative reporting at adoption.
Accordingly, we continue to apply the guidance of ASC 840, including
disclosure requirements, in our comparative periods prior to January 1,
2019.

Financial Outlook

Dropbox will provide forward-looking guidance in connection with this
quarterly earnings announcement on our conference call, webcast, and on
our investor relations website at investors.dropbox.com.

Conference Call Information

Dropbox plans to host a conference call today to review its first
quarter financial results and to discuss its financial outlook. This
call is scheduled to begin at 2:00 p.m. PT / 5:00 p.m. ET and can be
accessed by dialing (877) 300-7844 from the United States or (786)
815-8440 internationally with reference to the company name and
conference title, and a live webcast and replay of the conference call
can be accessed from the Dropbox investor relations website at investors.dropbox.com.
Following the completion of the call, a telephonic replay will be
available through 11:59 p.m. ET on May 16, 2019 at (855) 859-2056 from
the United States or (404) 537-3406 internationally with recording
access code 5191784.

Advertisement
Stake.com

Other Upcoming Events

Ajay Vashee, Chief Financial Officer, will be presenting at Bank of
America Merrill Lynch’s 2019 Global Technology Conference in San
Francisco, CA, on Tuesday, June 4, 2019 at 3:50 p.m. PT. At that time, a
live webcast will be accessible from the Dropbox investor relations
website at investors.dropbox.com.
Following the event, a replay will be made available at the same
location.

About Dropbox

Dropbox is a leading global collaboration platform that’s transforming
the way people work together, from the smallest business to the largest
enterprise. With more than 500 million registered users across 180
countries, our products are designed to establish a more enlightened way
of working. Headquartered in San Francisco, CA, Dropbox has 12 offices
around the world. For more information on our mission and products,
visit dropbox.com.

Use of Non-GAAP Financial Measures

Advertisement
Stake.com

Reconciliations of non-GAAP financial measures to the most directly
comparable financial results as determined in accordance with GAAP are
included at the end of this press release following the accompanying
financial data. For a description of these non-GAAP financial measures,
including the reasons management uses each measure, please see the
section of the tables titled “About Non-GAAP Financial Measures.”

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
including, among other things, statements regarding Dropbox’s future
operational performance, the demand for our platform and product
features, and the benefits from new product experiences and
acquisitions. Words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect,” “plans,” and similar
expressions are intended to identify forward-looking statements. Dropbox
has based these forward-looking statements largely on its current
expectations and projections about future events and financial trends
that the Company believes may affect its business, financial condition,
and results of operations. These forward-looking statements speak only
as of the date of this press release and are subject to risks,
uncertainties, and assumptions including, but not limited to: (i) our
ability to retain and upgrade paying users; (ii) our ability to attract
new users or convert registered users to paying users; (iii) our revenue
growth rate; (iv) our history of net losses; (v) our liability for any
unauthorized access to our data or our users’ content, including through
privacy and data security breaches; (vi) significant disruption of
service on our platform or loss of content; (vii) any decline in demand
for our platform or for content collaboration solutions in general;
(viii) changes in the interoperability of our platform across devices,
operating systems, and third-party applications that we do not control;
(ix) competition in our markets; (x) our ability to respond to rapid
technological changes, extend our platform, or develop new features;
(xi) our ability to manage our growth or plan for future growth; (xii)
our acquisition of other businesses and the potential of such
acquisitions to require significant management attention, disrupt our
business, or dilute stockholder value; and (xiii) the dual class
structure of our common stock and its effect of concentrating voting
control with certain stockholders who held our capital stock prior to
the completion of our initial public offering. Further information on
risks that could affect Dropbox’s results is included in our filings
with the Securities and Exchange Commission (“SEC”), including our Form
10-K for the year ended December 31, 2018. Additional information will
be made available in our quarterly report on Form 10-Q and other future
reports that we may file with the SEC from time to time, which could
cause actual results to vary from expectations. If the risks materialize
or assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. Dropbox
assumes no obligation to, and does not currently intend to, update any
such forward-looking statements after the date of this release, except
as required by applicable law.
   

Dropbox, Inc.

Condensed Consolidated Statements of Operations

Advertisement
Stake.com

(In millions, except per share data)

(Unaudited)

 
Three months ended
March 31,
2019     2018
Revenue $ 385.6 $ 316.3
Cost of revenue(1) 98.4   120.6  
Gross profit 287.2 195.7
Operating expenses(1):
Research and development 150.0 378.5
Sales and marketing 101.5 157.0
General and administrative 57.0   126.1  
Total operating expenses 308.5   661.6  
Loss from operations (21.3 ) (465.9 )
Interest income (expense), net 3.7 (1.2 )
Other income, net 4.2   3.4  
Loss before income taxes (13.4 ) (463.7 )
Benefit from (provision for) income taxes 5.7   (1.8 )
Net loss $ (7.7 ) $ (465.5 )
Net loss per share attributable to common stockholders, basic and
diluted
$ (0.02 ) $ (2.13 )
Weighted-average shares used in computing net loss per share
attributable to common stockholders, basic and diluted
410.5   218.8  
 
 
(1) Includes stock-based compensation expense as follows:
 
Three months ended
March 31,
2019 2018
Cost of revenue $ 3.0 $ 37.8
Research and development 30.5 282.9
Sales and marketing 7.1 72.4
General and administrative 15.0 93.4
 
   

Dropbox, Inc.

Condensed Consolidated Balance Sheets

(In millions)

Advertisement
Stake.com

(Unaudited)

 
As of
March 31, 2019     December 31, 2018
Assets
Current assets:
Cash and cash equivalents $ 359.2 $ 519.3
Short-term investments 556.0 570.0
Trade and other receivables, net 34.1 28.6
Prepaid expenses and other current assets 58.3   92.3  
Total current assets 1,007.6 1,210.2
Property and equipment, net 340.9 310.6
Operating lease right-of-use asset 430.4
Intangible assets, net 57.4 14.7
Goodwill 230.4 96.5
Other assets 61.9   62.1  
Total assets $ 2,128.6   $ 1,694.1  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 27.4 $ 33.3
Accrued and other current liabilities 148.8 164.5
Accrued compensation and benefits 36.4 80.9
Operating lease liability 74.1
Finance lease obligation 70.7 73.8
Deferred revenue 508.4   485.0  
Total current liabilities 865.8 837.5
Operating lease liability, non-current 441.5
Finance lease obligation, non-current 106.7 89.9
Other non-current liabilities(1) 9.7   89.9  
Total liabilities 1,423.7   1,017.3  
Stockholders’ equity:
Additional paid-in capital 2,377.8 2,337.5
Accumulated deficit (1,674.7 ) (1,659.5 )
Accumulated other comprehensive income (loss) 1.8   (1.2 )
Total stockholders’ equity 704.9   676.8  
Total liabilities and stockholders’ equity $ 2,128.6   $ 1,694.1  
 

(1) As of December 31, 2018 the Company had non-current
deferred rent of $81.0 million. As of March 31, 2019, deferred
rent is now included in the determination of the Company’s
operating lease right-of-use asset due to the adoption of ASC 842.

 
   

Dropbox, Inc.

Condensed Consolidated Statements of Cash Flows

(In millions)

Advertisement
Stake.com

(Unaudited)

 
Three months ended
March 31,
2019     2018
Cash flow from operating activities
Net loss $ (7.7 ) $ (465.5 )
Adjustments to reconcile net loss to net cash provided by operating
activities:
Depreciation and amortization 45.8 35.9
Stock-based compensation 55.6 486.5
Amortization of deferred commissions 3.9 2.4
Other (4.4 ) (0.6 )
Changes in operating assets and liabilities:
Trade and other receivables, net (5.1 ) 3.6
Prepaid expenses and other current assets (14.2 ) (1.5 )
Other assets 11.2 (5.7 )
Accounts payable (5.2 ) (2.8 )
Accrued and other current liabilities 10.0 8.8
Accrued compensation and benefits (45.9 ) (26.2 )
Deferred revenue 18.6 26.7
Other non-current liabilities (13.2 ) 0.2
Tenant improvement allowance reimbursement 13.8    
Net cash provided by operating activities 63.2   61.8  

Cash flow from investing activities

Capital expenditures (29.7 ) (9.9 )
Cash paid for business combinations, net of cash acquired (172.1 )
Purchases of short-term investments (153.0 ) (180.8 )
Proceeds from sales of short-term investments 110.2
Proceeds from maturities of short-term investments 66.6
Other 4.7   (2.4 )
Net cash used in investing activities (173.3 ) (193.1 )
Cash flow from financing activities
Proceeds from initial public offering and private placement, net of
underwriters’ discounts and commissions
638.2
Payments of deferred offering costs (0.9 )
Shares repurchased for tax withholdings on release of restricted
stock
(25.5 ) (241.2 )
Proceeds from issuance of common stock, net of repurchases 0.9 0.8
Principal payments on finance lease obligations (26.2 ) (29.8 )
Other (0.2 ) (2.1 )
Net cash provided by (used in) financing activities (51.0 ) 365.0  
Effect of exchange rate changes on cash and cash equivalents 1.0   1.6  
Change in cash and cash equivalents (160.1 ) 235.3
Cash and cash equivalents—beginning of period 519.3   430.0  
Cash and cash equivalents—end of period $ 359.2   $ 665.3  
 
Supplemental cash flow data:    
Property and equipment acquired under finance leases $ 39.9   $ 25.5  
 
               

Dropbox, Inc.

Three months ended March 31, 2019

Reconciliation of GAAP to Non-GAAP results

Advertisement
Stake.com

(In millions, except for percentages, which may not foot due to
rounding)

(Unaudited)

 
GAAP

Stock-based
compensation

Acquisition-
related and
other expenses

 

Intangibles
amortization

Advertisement
Stake.com
  Non-GAAP
Cost of revenue $ 98.4 $ (3.0 ) $ $ (0.6 ) $ 94.8
Cost of revenue margin 25.5 % (0.8 )% % (0.2 )% 24.6 %
Gross profit 287.2 3.0 0.6 290.8
Gross margin 74.5 % 0.8 % % 0.2 % 75.4 %
Research and development 150.0 (30.5 ) (2.3 ) 117.2
Research and development margin 38.9 % (7.9 )% (0.6 )% % 30.4 %
Sales and marketing 101.5 (7.1 ) (0.8 ) 93.6
Sales and marketing margin 26.3 % (1.8 )% % (0.2 )% 24.3 %
General and administrative 57.0 (15.0 ) (1.0 ) 41.0
General and administrative margin 14.8 % (3.9 )% (0.3 )% % 10.6 %
Income (loss) from operations $ (21.3 ) $ 55.6 $ 3.3 $ 1.4 $ 39.0
Operating margin (5.5 )% 14.4 % 0.9 % 0.4 % 10.1 %
 
               

Dropbox, Inc.

Three months ended March 31, 2018

Reconciliation of GAAP to Non-GAAP results

(In millions, except for percentages, which may not foot due to
rounding)

(Unaudited)

Advertisement
Stake.com
 
GAAP

Stock-based
compensation

Employer payroll
taxes related to the
release
of

two-tier RSUs

Non-GAAP
Cost of revenue $ 120.6 $ (37.8 ) $ (1.1 ) $ 81.7
Cost of revenue margin 38.1 % (12.0 )% (0.3 )% 25.8 %
Gross profit 195.7 37.8 1.1 234.6
Gross margin 61.9 % 12.0 % 0.3 % 74.2 %
Research and development 378.5 (282.9 ) (8.3 ) 87.3
Research and development margin 119.7 % (89.4 )% (2.7 )% 27.6 %
Sales and marketing 157.0 (72.4 ) (2.2 ) 82.4
Sales and marketing margin 49.6 % (22.9 )% (0.6 )% 26.1 %
General and administrative 126.1 (93.4 ) (2.3 ) 30.4
General and administrative margin 39.9 % (29.5 )% (0.8 )% 9.6 %
Income (loss) from operations $ (465.9 ) $ 486.5 $ 13.9 $ 34.5
Operating margin (147.3 )% 153.8 % 4.4 % 10.9 %
   

Dropbox, Inc.

Three months ended March 31, 2019 and 2018

Reconciliation of GAAP net loss to Non-GAAP net income and
Non-GAAP diluted net income per share

Advertisement
Stake.com

(In millions, except per share data)

(Unaudited)

 
Three months ended March 31,
2019     2018
GAAP net loss $ (7.7 ) $ (465.5 )
Stock-based compensation 55.6 486.5
Acquisition-related and other expenses 3.3
Amortization of acquired intangible assets 1.4
Employer payroll taxes related to the release of two-tier RSUs 13.9
Income tax effects of non-GAAP adjustments (10.9 ) (4.0 )
Non-GAAP net income $ 41.7   $ 30.9  
Non-GAAP diluted net income per share $ 0.10   $ 0.08  
Weighted-average shares used to compute Non-GAAP diluted net income
per share
417.7   373.1  
 
   

Dropbox, Inc.

Three months ended March 31, 2019 and 2018

Reconciliation of free cash flow and supplemental cash flow
disclosure

Advertisement
Stake.com

(In millions, except for percentages)

(Unaudited)

 
Three months ended March 31,
2019     2018
Free cash flow reconciliation:
Net cash provided by operating activities $ 63.2 $ 61.8
Less:
Capital expenditures (29.7 ) (9.9 )
Free cash flow $ 33.5   $ 51.9  
Free cash flow margin 8.7 % 16.4 %
Supplemental disclosures:
Capital expenditures related to our new corporate headquarters, net
of tenant improvement allowances(1)
$ 7.5   $ 0.6  
 

(1) Capital expenditures include cash outflows related
to the build-out of our new corporate headquarters in San
Francisco, CA. Net cash provided by operating activities include
tenant improvement allowances related to our new corporate
headquarters, and represents cash received from our landlord to
partially offset this build-out. These amounts are presented net
in the table above.

 

About Non-GAAP Financial Measures

To provide investors and others with additional information regarding
Dropbox’s results, we have disclosed the following non-GAAP financial
measures: non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP
operating expenses (including research and development, sales and
marketing and general and administrative), non-GAAP income from
operations, non-GAAP net income, free cash flow (“FCF”) and non-GAAP
diluted net income per share. Dropbox has provided a reconciliation of
each non-GAAP financial measure used in this earnings release to the
most directly comparable GAAP financial measure. Non-GAAP cost of
revenue, gross profit, operating expenses, income from operations, and
net income differs from GAAP in that it excludes stock-based
compensation expense, amortization of acquired intangible assets, other
acquisition-related expenses, which include third-party diligence costs
and compensation expense for key acquired personnel, and employer
payroll tax expense relating to the release of two-tier RSUs in
connection with our initial public offering during the three months
ended March 31, 2018. Non-GAAP net income also includes the income tax
effect of these adjustments, including the tax effects of acquired
intangible assets. FCF differs from GAAP net cash provided by operating
activities in that it treats capital expenditures as a reduction to net
cash provided by operating activities. Free cash flow margin is
calculated as FCF divided by revenue. Non-GAAP diluted net income per
share differs from GAAP diluted net loss per share in that the numerator
utilizes the non-GAAP net income as described above, and the
weighted-average shares used in the computation include certain shares
that are excluded from the GAAP diluted net loss per share calculation
because their effect would have been anti-dilutive.

Advertisement
Stake.com

Dropbox’s management uses these non-GAAP financial measures to
understand and compare operating results across accounting periods, for
internal budgeting and forecasting purposes, for short and long-term
operating plans, and to evaluate Dropbox’s financial performance and the
ability to generate cash from operations. Management believes these
non-GAAP financial measures reflect Dropbox’s ongoing business in a
manner that allows for meaningful period-to-period comparisons and
analysis of trends in Dropbox’s business, as they exclude expenses that
are not reflective of ongoing operating results. Management also
believes that these non-GAAP financial measures provide useful
supplemental information to investors and others in understanding and
evaluating Dropbox’s operating results and future prospects in the same
manner as management and in comparing financial results across
accounting periods and to those of peer companies.

We believe that the non-GAAP financial measures, non-GAAP cost of
revenue, gross profit, operating expenses, income from operations, net
income, and diluted net income per share are meaningful to investors
because they help identify underlying trends in our business that could
otherwise be masked by the effect of the expenses that we exclude.

We believe that FCF is an indicator of our liquidity over the long term,
and provides useful information regarding cash provided by operating
activities and cash used for investments in property and equipment
required to maintain and grow our business. FCF is presented for
supplemental informational purposes only and should not be considered a
substitute for financial information presented in accordance with GAAP.
FCF has limitations as an analytical tool, and it should not be
considered in isolation or as a substitute for analysis of other GAAP
financial measures, such as net cash provided by operating activities.
Some of the limitations of FCF are that FCF does not reflect our future
contractual commitments, excludes investments made to acquire assets
under capital leases, includes capital expenditures related to our new
corporate headquarters, and may be calculated differently by other
companies in our industry, limiting its usefulness as a comparative
measure.

The use of non-GAAP cost of revenue, gross profit, operating expenses,
income from operations, net income, free cash flow, and diluted net
income per share measures has certain limitations as they do not reflect
all items of income, expense, and cash expenditures, as applicable, that
affect Dropbox’s operations. Dropbox compensates for these limitations
by reconciling the non-GAAP financial measures to the most comparable
GAAP financial measures. Additionally, we have provided supplemental
disclosures in our reconciliation of net cash provided by operating
activities to free cash flow to include capital expenditures related to
our new corporate headquarters, net of tenant improvement allowances.
These non-GAAP financial measures should be considered in addition to,
not as a substitute for or in isolation from, measures prepared in
accordance with GAAP. Further, these non-GAAP measures may differ from
the non-GAAP information used by other companies, including peer
companies, and therefore comparability may be limited. Management
encourages investors and others to review Dropbox’s financial
information in its entirety and not rely on a single financial measure.

Advertisement
Stake.com

Contacts

Investors:
Darren Yip
ir@dropbox.com
or
Media:
Saman
Asheer
press@dropbox.com


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania